ANIX News and Press, Anixa Biosciences Inc. From 08/14/23

Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit PR Newswire SAN JOSE, Calif. , Aug. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c...

SAN JOSE, CA / ACCESSWIRE / August 10, 2023 / Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the human immune system has led to the development of...

Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial PR Newswire SAN JOSE, Calif. , Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechno...

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology PR Newswire SAN JOSE, Calif. , July 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company f...

Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology PR Newswire — Technology currently being evaluated for the treatment of ovarian cancer in Phase 1 clinical trial — SAN JOSE, Calif. , July 11, 2023 ...

2023-07-11 08:20:47 ET Viridian Therapeutics VRDN -19% following thyroid eye disease asset data . ADC Therapeutics ( ADCT ) -16% announces voluntary pause of enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA and Rituximab in unfit or frail previously untre...

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial PR Newswire SAN JOSE, Calif. , May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevent...

2023-04-18 19:13:41 ET Summary Anixa just released the first efficacy data for its triple-negative breast cancer vaccine candidate. Triple-negative breast cancer is the most aggressive and deadly form of breast cancer. The safety and efficacy data are promising and could allow...

Anixa Biosciences Clarifies Poster Presentation on Company Website PR Newswire SAN JOSE, Calif. , April 17, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced ...

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine PR Newswire Immune responses were observed at all dose levels SAN JOSE, Calif. , April 17, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: AN...